Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Roche makes milestone payment to retain option to MEM-3454

May 5, 2005

NGF gene therapy shows promise in the treatment of Alzheimer's disease

May 5, 2005

Pharmacokinetics and pharmacodynamics of CHF-3381 studied in healthy volunteers

May 4, 2005

NDA submission for Emezine

May 4, 2005

Migenix receives Canadian clearance for phase I/II study of MX-4509

May 4, 2005

Phase I gene therapy study for Parkinson's nears completion

May 3, 2005

Promising results reported with a lingual spray formulation of alprazolam

May 3, 2005

Kynurenine 3-monooxygenase: a therapeutic target for Huntington disease

May 3, 2005

CHEC-9 blocks sPLA2 activity in vitro and in vivo / News in Context

April 29, 2005

NDA for tetrabenazine for chorea associated with Huntington's disease

April 29, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...